Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mount, D. W.
Right arrow Articles by Pandey, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mount, D. W.
Right arrow Articles by Pandey, R.
Related Collections
Right arrow Therapeutics and Targets
Right arrow Therapeutics and Targets: Identification, Validation, and Markers
Right arrow Cellular Pathobiology: Cancer Genes and Genomics
Mol Cancer Ther. 2005;4:1636-1643
© 2005 American Association for Cancer Research

Minireview

Using bioinformatics and genome analysis for new therapeutic interventions

David W. Mount and Ritu Pandey

Arizona Cancer Center, University of Arizona, Tucson, Arizona

Requests for reprints: David W. Mount, Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, P.O. Box 245024, Tucson, AZ 85724-5024. Phone: 520-626-0390; Fax: 520-626-6898. E-mail: mount{at}u.arizona.edu

The genome era provides two sources of knowledge to investigators whose goal is to discover new cancer therapies: first, information on the 20,000 to 40,000 genes that comprise the human genome, the proteins they encode, and the variation in these genes and proteins in human populations that place individuals at risk or that occur in disease; second, genome-wide analysis of cancer cells and tissues leads to the identification of new drug targets and the design of new therapeutic interventions. Using genome resources requires the storage and analysis of large amounts of diverse information on genetic variation, gene and protein functions, and interactions in regulatory processes and biochemical pathways. Cancer bioinformatics deals with organizing and analyzing the data so that important trends and patterns can be identified. Specific gene and protein targets on which cancer cells depend can be identified. Therapeutic agents directed against these targets can then be developed and evaluated. Finally, molecular and genetic variation within a population may become the basis of individualized treatment.


Grant support: National Cancer Institute grants, particularly the Arizona Cancer Center Core Grant and startup funds provided by Dr. Daniel Von Hoff; Southwest Environmental Health Sciences Center Core Grant and startup funds from Dr. Serrine Lau.

1 A comprehensive list of web sites referred to appears in the Appendix.

Received 5/13/05; revised 7/28/05; accepted 8/11/05.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.